Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157 10mg Dosage Protocol | PeptideDosages.com

BPC-157 (10 mg Vial) Dosage Protocol BPC-157 Dosage Chart BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for resea

BPC-157 (10 mg Vial) Dosage Protocol

BPC-157 Dosage Chart

BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.

Typical daily range: 200–600 mcg once daily (gradual titration).

Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence studied for tissue-healing and cytoprotective properties[1][2]. Preclinical models demonstrate accelerated wound repair and anti-inflammatory activity[3], though human clinical data remain limited to early-phase safety trials and small case reports[4][5]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read BPC-157 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Weeks 1–2

200 mcg (0.2 mg)

6 units (0.06 mL)

Weeks 3–4

400 mcg (0.4 mg)

12 units (0.12 mL)

Weeks 5–8+

600 mcg (0.6 mg)

18 units (0.18 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 5 for better accuracy. Dosing is extrapolated from preclinical models[1][6]; human clinical validation remains limited.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (BPC-157, 10 mg each):

8 weeks ≈ 3 vials (25.2 mg used)

12 weeks ≈ 5 vials (42 mg used)

16 weeks ≈ 6 vials (58.8 mg used)

Insulin Syringes (U-100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (3 vials): 9 mL → 1 × 10 mL bottle

12 weeks (5 vials): 15 mL → 2 × 10 mL bottles

16 weeks (6 vials): 18 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100-count boxes

12 weeks: 168 swabs → recommend 2 × 100-count boxes

16 weeks: 224 swabs → recommend 3 × 100-count boxes

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Protocols and Research-Grade Peptide Considerations

BPC-157 studied chronic fatigue research typically uses subcutaneous injection protocols ranging from 250mcg to 500mcg twice daily, administered in cycles of 4–8 weeks. The peptide's half-life is approximately 4 hours, which explains the twice-daily dosing: maintaining therapeutic plasma levels requires split administration rather than a single large dose. Injectable forms bypass first-pass hepatic metabolism, delivering higher bioavailability than oral formulations. Critical when targeting systemic mitochondrial and gut-barrier effects rather than localized tissue repair. Reconstitution accuracy determines peptide stability. BPC-157 arrives as a lyophilized powder requiring reconstitution with bacteriostatic water at a 1:1 ratio (1ml water per 5mg peptide yields a 5mg/ml solution). Once reconstituted, the peptide must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation. The most common error we've observed in research settings isn't injection technique; it's improper storage leading to degraded peptides that deliver zero therapeutic effect despite correct dosing protocols. Purity verification is non-negotiable when studying immune-sensitive conditions like chronic fatigue. Bacterial endotoxins present in low-purity peptides can trigger the exact inflammatory cascades you're attempting to suppress. Certificate of analysis (CoA) documentation from independent labs. Not supplier-generated reports. Shoul…
SIDE EFFECTS

Risks & Side Effects

Because BPC-157 is not FDA-approved and lacks large human safety trials, its full safety profile is unknown. Potential risks may include: Injection-site reactions Local irritation Headache Nausea Dizziness Fatigue Allergic or hypersensitivity reactions Immune reaction to peptide impurities or aggregation Infection risk with injectable products Unknown long-term safety Unknown effects on abnormal tissue growth Theoretical concern in patients with active malignancy due to possible angiogenic and tissue-growth signaling effects The FDA has stated that compounded drugs containing BPC-157 may present safety concerns and that available information is insufficient to determine whether the drug would cause harm when administered to humans.
02

Question drills

Open a question for its connected answer.

01What If My RA Is Mild — Could BPC-157 Replace Methotrexate?+

No evidence supports BPC-157 as monotherapy for RA. The rodent studies used peptide administration alongside disease induction, not as a replacement for established anti-rheumatic agents. Methotrexate slows radiographic progression in 60–70% of early RA patients; stopping a proven therapy to trial an unvalidated peptide carries significant risk of irreversible joint damage. BPC-157 might serve as an adjunct to reduce symptom burden or support tissue repair, but it has not demonstrated disease-modifying efficacy in the absence of concurrent RA therapy.

SOURCE / realpeptides.co ↗
02What If I'm Experiencing Chemotherapy-Induced Peripheral Neuropathy?+

Chemotherapy-induced peripheral neuropathy (CIPN) results from direct neurotoxic damage to axons and dorsal root ganglia. Particularly with platinum-based agents (cisplatin, oxaliplatin) and taxanes (paclitaxel). BPC-157 studied neuropathy research hasn't specifically tested CIPN models, though the axonal regeneration effects seen in crush injury models suggest potential relevance. The critical unknown: timing. Does the peptide prevent damage if administered during chemotherapy, or only promote repair after treatment ends? No published research addresses this.

SOURCE / realpeptides.co ↗
03What If BPC-157 Doesn't Work After Four Weeks?+

If golfer's elbow symptoms haven't improved after 28 days of BPC-157 administration at research-equivalent doses, the peptide either isn't effective in your case or the underlying pathology involves more than vascular insufficiency. Chronic tendinopathy that's progressed to significant tendon degeneration (visible on ultrasound as hypoechoic regions or calcification) may not respond to angiogenic peptides alone because the structural damage exceeds what enhanced blood flow can repair. At that point, you're looking at mechanical intervention. Platelet-rich plasma injection, needle tenotomy, or surgical debridement. BPC-157 studied golfer's elbow trials showed effects within 14–21 days in animal models; if you're seeing zero subjective improvement (no reduction in pain with resisted wrist flexion, no increase in grip strength) after three weeks, continuing beyond four weeks is unlikely to change the outcome.

SOURCE / realpeptides.co ↗
04What If I Experience Multiple Concussions Over a Season — Does Repeated BPC-157 Use Cause Tolerance?+

No published evidence suggests receptor downregulation or tolerance development with repeated BPC-157 administration in TBI models. The peptide's mechanism. FAK-paxillin pathway activation, VEGFR2 stabilization, microglial phenotype shifting. Doesn't involve desensitization-prone receptor classes like opioid or adrenergic receptors. The concern with repeated concussions isn't peptide tolerance; it's cumulative axonal damage that no intervention fully prevents. Each subsequent concussion occurs on a substrate of partially healed tissue with reduced metabolic reserve, and BPC-157 studied concussion recovery doesn't reverse the underlying vulnerability that repeat injuries create.

SOURCE / realpeptides.co ↗
05What if I need to verify peptide purity before starting research in Raleigh?+

Every Real Peptides order shipped to Raleigh includes a certificate of analysis (COA) from an ISO-certified third-party lab, listing HPLC purity, mass spectrometry confirmation, and endotoxin testing results. You can request advance COA review before purchase by contacting support with the specific product and lot number. This documentation is the same standard used by Wake County research institutions and satisfies institutional review board requirements for peptide sourcing verification.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Comparative Approaches to GI Support in Research

When considering BPC-157 GI protection, it's helpful to understand how its mechanisms compare to other research approaches for supporting gastrointestinal health. This table outlines some key differences and why BPC-157 presents a unique avenue for investigation. Primary Mechanism Direct tissue regeneration, angiogenesis, anti-inflammatory, cytoprotective, tight junction stabilization, growth factor modulation. Modulating gut microbiota, producing beneficial metabolites, enhancing barrier function indirectly, immune system modulation. Suppressing inflammatory pathways (e.g., COX inhibition) to reduce pain and swelling. Focus of Action Directly on damaged epithelial cells, vascular system, and inflammatory cascades within the gut lining. Primarily on the microbial ecosystem; indirect effects on host physiology through microbial interactions. Systemic or localized inflammation; does not directly promote tissue regeneration or angiogenesis. Repair & Regeneration High potential for direct tissue repair, accelerating wound healing, and restoring structural integrity. Indirectly supports epithelial health through microbial balance; limited direct regenerative capacity. Minimal direct regenerative properties; primarily focused on symptom management and inflammation reduction. Versatility Broad applicability across various types of GI damage (ulcers, inflammation, leaky gut models). Strain-specific effects; efficacy varies greatly depending on the type of probiotic and specific GI condition being studied. Targeted for inflammation; may have side effects on GI mucosa with prolonged use, potentially exacerbating some issues. Research Appeal in 2026 Cutting-edge, high interest for regenerative medicine and complex GI pathologies. Established but continually evolving; focus on strain specificity and precision microbiome engineering. Well-understood, but often associated with side effects, driving research into alternatives. This comparison highlights BPC-157's distinctive role as a powerful research tool focused on fundamental regenerative processes, offering a compelling alternative to more symptomatic or indirect approaches. The direct impact of BPC-157 GI protection on tissue healing is what truly sets it apart.

RESEARCH

Gastrointestinal Research

BPC-157 has the longest preclinical track record in GI research. Laboratory studies in rodent models have examined its effects on gastric ulcer healing, intestinal anastomosis repair, inflammatory bowel models, and NSAID-induced mucosal damage. Researchers continue to investigate the nitric oxide pathway as a central mediator of BPC-157 activity in GI tissue models.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Studied Diabetic Neuropathy Research: Comparison

BPC-157 VEGF upregulation + anti-inflammatory cytokine modulation 28–34% improvement in sciatic nerve conduction velocity at 10–100 mcg/kg over 21–28 days (rat models) 41% reducti…

Comparison

BPC-157 Studied Plantar Fasciitis: Clinical vs Research Context Comparison

Animal tendon injury models 30+ published studies showing accelerated healing, increased tensile strength, organised collagen deposition Research use only. Not subject to clinical…

Comparison

BPC-157 50s Age Protocol Comparison

Acute soft tissue strain (hamstring, calf) 250–350mcg daily Subcutaneous near strain site 4–5 weeks Functional improvement weeks 2–3 Chronic tendinopathy (rotator cuff, Achilles) …